Top Story

Illumina announces collaborative partnership to develop oncology companion diagnostics

August 21, 2014

Illumina Inc. announced it has formed collaborative partnerships with AstraZeneca, Janssen Biotech Inc. and Sanofi to develop a universal next-generation sequencing-based oncology test system.

The novel system is intended for clinical trials of targeted cancer therapies with the objective of developing a multi-gene panel for therapeutic selection, which could provide a more comprehensive tool for precision medicine.

figure In the Journals

Bisphosphonate treatment did not reduce risk for postmenopausal breast cancer

August 21, 2014
Treatment with bisphosphonates for osteoporosis provided no protective effect against the risk for invasive postmenopausal breast cancer, according to an analysis of…
figure In the Journals

Digital surveillance, photography aided early melanoma diagnosis

August 21, 2014
Surveillance with total body photography and sequential digital dermoscopy imaging helped improve early detection of primary melanomas, according to study…
figure In the Journals

Pemetrexed plus cisplatin active in advanced, recurrent cervical carcinoma

August 21, 2014
The combination of pemetrexed and cisplatin appeared safe and effective in women with advanced, persistent or recurrent carcinoma of the cervix, according to results of…
More News Headlines »
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »
CME

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

8/16/2014
Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »